Summary
6-[Bis-(2-chloroethyl)-amino]-6-deoxy-D-glucose (C-6) is a new glucose-containing nitrogen mustard that has significant activity for murine P388 leukemia with relative sparing of bone marrow in mice. The in vitro myelotoxicity of C-6 compared with that of melphalan, a clinically active, myelosuppressive nitrogen mustard, was determined in the CFU-C assay in human bone marrow samples obtained from normal volunteers. There was no significant difference between the myelosuppressive actions of C-6 and melphalan at any of the concentrations used except for 4.0 μM, at which C-6 was significantly (P0.05) more toxic than melphalan. Both agents decreased the number of bone marrow cell colonies to approximately 12% of control at 6.6 μM (1 h incubation), which is a good approximation of melphalan's CxT (concentration by time) in man.
We used the human tumor stem cell assay (HTSCA) to investigate in vitro antitumor activity. We obtained two specimens of malignant melanoma and two of malignant ovarian carcinoma from patients not previously treated with chemotherapy. The antitumor activity of melphalan was either similar to or greater than that of C-6 at all concentrations utilized against any of the four tumor specimens, except at 1.3 μM for tumor I. In particular, there was no significant difference in the antitumor activities of the two agents at 6.6 μM. These results suggest that C-6 will not be less myelosuppressive than melphalan at doses that produce equivalent antitumor activity in man.
In addition, C-6 did not demonstrate increased myelotoxicity for normal human bone marrow cells incubated in glucose-deficient medium as against medium containing 300 mg% glucose at any of the concentrations used. This suggests that C-6 is not transported into normal human bone marrow cells via the glucose transport system, despite the presence of a glucose moiety within the molecale.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Alberts DS, Chang SY, Chen HS, Moon TE, Evans TL, Furner RL, Himmelstein K, Gross JF (1979) Kinetics of intravenous melphalan. Clin Pharmacol Ther 26:73–80
Anderson T, McMenamin MG, Schein PS (1973) Chlorozotocin, 2-[3-(2-chloroethyl)-3-nitrosoureido]-D-glucopyranose, an antitumor agent with modified bone marrow toxicity. Cancer Res 33:2005–2009
Cantrell JE Jr, Green DC, Tew KD, Schein PS (1982) A comparison of the relative murine myelotoxicities of 6-bis-(2-chloroethyl)-amino-6-deoxy-D-glucose (C-6), D and L isomers of 2,3,4,6-tetra-0-acetyl N,N-bis(2-chloroethyl)-glucopyranosylamine (C-1D and C-1L), and nitrogen mustard. Proc Am Assoc Cancer Res 23:165
Chabner BA, Myers CE, Olverio VT (1977) Clinical pharmacology of anticancer drugs. Semin Oncol 4:165–190
Dufour M, St.Germain J, Skalski V, Dorato A, Lazarus P, Panasci L (1984) Effect of administration of sodium cyanate and melphalan on the lifespan of P388 tumor-bearing CD2F1 mice. Cancer Chemother Pharmacol 12:94–97
Green D, Smulson ME, Schein PS (1979) Differential binding of chlorozotocin (CLZ) and CCNU to murine bone marrow chromatin. Proc Am Assoc Cancer Res 20:253
Hamburger AW, Salmon SE (1977) Primary bioassay of human myeloma stem cells. J Clin Invest 60:846–854
Hamburger AW, White CP, Tencer K (1982) Effect of enzymatic disaggregation on proliferation of human tumor cells in soft agar. JNCI 68:945–949
Hoth D, Woolley P, Green D, MacDonald J, Schein PS (1978) Phase I studies on chlorozotocin. Clin Pharmacol Ther 23:712–722
Johnston TP, McCaleb GS, Montgomery JA (1975) Synthesis of chlorozotocin, the 2-chloroethyl analog of the anti-cancer antibiotic streptozotocin. J Med Chem 18:104–106
Lam H-YP, Talgoy MM, Goldenberg GJ (1980) Uptake and decomposition of chlorozotocin in L5178Y lymphoblasts in vitro. Cancer Res 40:3950–3955
Lazarus P, St.Germain J, Dufour M, Palmer G, Wallace D, Panasci LC (1983) Comparison of the transport of chlorozotocin and CCNU in L1210 leukemia and murine bone marrow cells in vitro. Cancer Chemother Pharmacol 11:159–161
Moon TE, Thompson SP, Salmon SE, Meyskens FL (1983) A quantitative model of the in vitro growth of melanoma cells. Proc Am Assoc Cancer Res 24:49
Panasci L, Green D, Nagourney R, Fox P, Schein PS (1977a) A structure-activity analysis of chemical and biological parameters of chloroethylnitrosoureas in mice. Cancer Res 37: 2615–2618
Panasci L, Fox PA, Schein PS (1977b) Structure-activity studies of methylnitrosourea antitumor agents with reduced bone marrow toxicity. Cancer Res 37:3321–3328
Panasci L, Green A, Fox P, Schein PS (1979) Chlorozotocin: Mechanism of reduced bone marrow toxicity in mice. J Clin Invest 64:1103–1111
Panasci L, Comis R, Ginsberg S, Kohn L, Fitzpatrick A, Rupert M, Scalzo T (1981) Phase I trial of chlorozotocin: Attempted amelioration of myelotoxicity by glucose administration. Cancer Treat Rep 65:647–650
Pike B, Robinson WA (1970) Human bone marrow culture in agar gel. J Cell Physiol 76:77–84
Salmon SE, Hamburger AW, Soehnlen B, Durie BG, Alberts DS, Moon TE (1978) Quantitation of differential sensitivity of human tumor stem cells to anticancer drugs. N Engl J Med 298:1321–1327
Schein PS, Panasci L, Woolley PV, Anderson T (1976) Pharmacology of chlorozotocin. A new nitrosourea antitumor agent. Cancer Chemother Rep 60:801–805
Schein PS, Bull JM, Doukas D, Hoth D (1978) Sensitivity of human and murine hematopoietic precursor cells to 2-[3-(2-chloroethyl)-3-nitrosoureido]-D-glucopyranose and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 38:257–260
Snedecor GW, Cochran WG (1967) One-way classifications. Analysis of variance. In: Statistical methods. Iowa State University Press, Ames, pp 258–298
Van Hoff DD, Clark GM, Stogdill BJ, Sarosdy MF, O'Brien MT, Casper MT, Mattox DE, Page CP, Cruz AB, Sandbach JF (1983) Prospective clinical trial of a human tumor cloning system. Cancer Res 43:1926–1931
Author information
Authors and Affiliations
Additional information
Supported by Grant RO1 CA28984, a grant from the National Cancer Institute of Canada, a private contribution from Mr Schiff
Rights and permissions
About this article
Cite this article
Lazarus, P., Dufour, M., Isabel, G. et al. In vitro comparative studies of the myelotoxicity and antitumor activity of 6-[bis-(2-chloroethyl)-amino]-6-deoxy-D-glucose versus melphalan utilizing the CFU-C and HTSCA assays. Cancer Chemother. Pharmacol. 16, 148–152 (1986). https://doi.org/10.1007/BF00256165
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00256165